Patents by Inventor Sabina Maria Ganter

Sabina Maria Ganter has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • TABLET FORMULATIONS COMPRISING VALSARTAN
    Publication number: 20130237574
    Abstract: The invention relates to solid oral dosage forms comprising pharmacologically effective amounts of valsartan or a pharmaceutically acceptable salt thereof or hydrate thereof. The compositions are at least 1.2 times more bioavailable than conventional valsartan capsule.
    Type: Application
    Filed: August 3, 2012
    Publication date: September 12, 2013
    Applicant: NOVARTIS AG
    Inventors: Sabina Maria Ganter, Robert Frank Wagner
  • ADDITIONAL THERAPEUTIC USE
    Publication number: 20120010258
    Abstract: The invention relates to the use of an AT1 receptor antagonist or an AT2 receptor modulator, respectively, or a pharmaceutically acceptable salt thereof, for producing a pharmaceutical preparation for the treatment of conditions or diseases associated with the increase of AT1 receptors in the sub-epithelial area or increase of AT2 receptors in the epithelia.
    Type: Application
    Filed: June 13, 2011
    Publication date: January 12, 2012
    Inventors: Gillian Rosemary Bullock, Marc De Gasparo, Sabina Maria Ganter
  • TABLET FORMULATIONS COMPRISING VALSARTAN
    Publication number: 20100267789
    Abstract: The invention relates to solid oral dosage forms comprising pharmacologically effective amounts of valsartan or a pharmaceutically acceptable salt thereof or hydrate thereof. The compositions are at least 1.2 times more bioavailable than conventional valsartan capsule.
    Type: Application
    Filed: July 1, 2010
    Publication date: October 21, 2010
    Applicant: NOVARTIS AG
    Inventors: Sabina Maria Ganter, Robert Frank Wagner
  • ADDITIONAL THERAPEUTIC USE
    Publication number: 20100120877
    Abstract: The invention relates to the use of an AT1 receptor antagonist or or an AT2 receptor modulator, respectively, or a pharmaceutically acceptable salt thereof, for producing a pharmaceutical preparation for the treatment of conditions or diseases associated with the increase of AT1 receptors in the sub-epithelial area or increase of AT2 receptors in the epithelia.
    Type: Application
    Filed: September 25, 2008
    Publication date: May 13, 2010
    Inventors: Gillian Rosemary Bullock, Marc De Gasparo, Sabina Maria Ganter
  • Tablet formulations comprising valsartan
    Publication number: 20030152620
    Abstract: The invention relates to solid oral dosage forms comprising pharmacologically effective amounts of valsartan or a pharmaceutically acceptable salt thereof or hydrate thereof. The compositions are at least 1.2 times more bioavailable than conventional valsartan capsule.
    Type: Application
    Filed: February 25, 2003
    Publication date: August 14, 2003
    Inventors: Sabina Maria Ganter, Robert Frank Wagner
  • Additional therapeutic use
    Publication number: 20020155986
    Abstract: The invention relates to the use of an AT1 receptor antagonist or or an AT2 receptor modulator, respectively, or a pharmaceutically acceptable salt thereof, for producing a pharmaceutical preparation for the treatment of conditions or diseases associated with the increase of AT1 receptors in the sub-epithelial area or increase of AT2 receptors in the epithelia.
    Type: Application
    Filed: February 6, 2002
    Publication date: October 24, 2002
    Inventors: Gillian Rosemary Bullock, Marc De Gasparo, Sabina Maria Ganter
  • Additional therapeutic use
    Patent number: 6465502
    Abstract: The invention relates to the use of an AT1 receptor antagonist or or an AT2 receptor modulator, respectively, or a pharmaceutically acceptable salt thereof, for producing a pharmaceutical preparation for the treatment of conditions or diseases associated with the increase of AT1 receptors in the sub-epithelial area or increase of AT2 receptors in the epithelia.
    Type: Grant
    Filed: December 21, 1999
    Date of Patent: October 15, 2002
    Assignee: Novartis AG
    Inventors: Gillian Rosemary Bullock, Marc De Gasparo, Sabina Maria Ganter
  • Tablet formulations comprising valsartan
    Publication number: 20020132839
    Abstract: The invention relates to solid oral dosage forms comprising pharmacologically effective amounts of valsartan or a pharmaceutically acceptable salt thereof or hydrate thereof. The compositions are at least 1.2 times more bioavailable than conventional valsartan capsule.
    Type: Application
    Filed: June 22, 2001
    Publication date: September 19, 2002
    Inventors: Sabina Maria Ganter, Robert Frank Wagner